By Dr Derek Jellinek
28 April 2021, 4:50 PM
Ongoing elevated demand for PPE and product supply on track to meet that
demand saw the company provide a favourable trading update and upgrade
guidance, again.
Read more...
By Scott Power
15 April 2021, 8:00 AM
Morgans Senior Analyst Scott Power speaks with Chief Executive Officer of Control Bionics, Rob Wong, on the significant progress the healthcare company is making.
Read more...
By Scott Power
12 April 2021, 3:30 PM
Mach7 Technologies 3QFY21 result has restored investor confidence. Pleasingly, A$12.8m in new sales orders were generated for the quarter.
Read more...
By Iain Wilkie
30 March 2021, 4:00 PM
Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.
Read more...
By Scott Power
18 March 2021, 11:15 AM
Volpara has announced its largest contract to date worth over US$400,000. The next catalyst will be an increasing ARPU to be reported in the 4QFY21 cashflow report.
Read more...
By Dr Derek Jellinek
15 March 2021, 3:10 PM
While we make no changes to our estimates or price target, we believe CSL share weakness offers an opportunity to buy a high-quality business at a discount.
Read more...
By Dr Derek Jellinek
18 February 2021, 4:30 PM
In CSL Ltd's 1H21 results, Seqirus was the standout on pandemic driven demand for influenza vaccines, while Behring gained from Albumin sales and cost-outs, but Ig growth was modest and Specialty /Haemophilia fairly flat.
Read more...
By Dr Derek Jellinek
10 February 2021, 9:00 AM
We highlight our expectations for the following ahead of Reporting Season First Half 2021: ResMed, Sonic Healthcare, Virtus Health, Monash IVF, Volpara, Pro Medicus, and Mach7 Technologies. Watch now.
Read more...
By Scott Power
07 January 2021, 4:50 PM
In my latest network delivery, I run through a number of key themes that have our interest in the Healthcare space for 2021. I also touch on a number of upcoming catalysts.
Read more...
By Iain Wilkie
17 November 2020, 11:00 AM
Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.
Read more...